SCHEDULE: Rosalind Group Discloses 9.9% Biofrontera Stake

Rosalind Advisors and related entities report a 9.9% beneficial ownership in Biofrontera Inc., constrained by a 9.99% blocker provision on convertible securities.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively report beneficial ownership of 14,432,072 shares of Biofrontera Inc. Common Shares.
• This represents 9.9% of the class, calculated based on 10,138,567 common stock outstanding as of July 15, 2025.
• The reported aggregate amount includes 976,448 common shares, 10,733,278 shares issuable upon exercise of preferred shares, and 2,722,346 shares issuable upon exercise of convertible debt.
• A 'blocker provision' prevents the exercise of preferred shares and convertible debt if it would result in beneficial ownership exceeding 9.99% of the Common Stock.
• Due to this blocker, the reporting persons were unable to exercise any of the preferred shares or convertible debt as of the event date (June 30, 2025).
• The actual number of common shares beneficially owned, after giving effect to the blocker, is 976,448, representing approximately 9.63% of the common stock.
• The securities were acquired and are held in the ordinary course of business, not for changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While the blocker provision limits immediate conversion, the continued significant stake by Rosalind entities indicates ongoing investor interest. The filing is primarily a disclosure of ownership, not a performance update.

Positives

• A significant institutional investor group maintains a substantial stake, indicating continued interest in Biofrontera Inc.
• The disclosure clarifies the beneficial ownership structure, providing transparency to the market.

Negatives

• The 'blocker provision' limits the immediate convertibility and exercise of a large portion of the reported beneficial ownership (13,455,624 shares from preferred and convertible debt), preventing the holders from fully realizing their potential stake.
• The inability to exercise preferred shares and convertible debt due to the blocker means the reported 14.4 million shares are not fully liquid or immediately convertible into common stock beyond the 9.99% threshold.

Risks

• Conversion Limitations: The blocker provision prevents the full conversion and exercise of preferred shares and convertible debt if it results in beneficial ownership exceeding 9.99%, limiting the reporting persons' ability to increase their direct common stock holdings.
• Potential Dilution: While currently blocked, the eventual conversion of preferred shares and convertible debt could lead to significant dilution for existing common shareholders if the blocker is removed or the ownership threshold is adjusted.
• Control Limitations: The reporting persons explicitly state they do not intend to change or influence control, but the blocker provision inherently limits their ability to exert greater control through increased common share ownership.

Future Outlook

The filing does not provide forward-looking statements or guidance regarding Biofrontera Inc.'s future operations or financial performance, focusing solely on beneficial ownership disclosure.

Industry Context

This filing is a standard disclosure of significant beneficial ownership by an institutional investor group in a publicly traded company. It does not provide broader industry trends or competitive analysis, focusing specifically on the ownership structure of Biofrontera Inc.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake and the limitations on their ability to convert certain securities, which could influence perceptions of control and potential future dilution.
• Management: Clarifies the ownership structure and the intent of a major investor, which is stated as not for changing or influencing control.

Key Dates

Recommendation

This Schedule 13G filing primarily provides an update on the beneficial ownership of Biofrontera Inc. by Rosalind Advisors and related entities. It confirms a significant, but capped, stake due to a 9.99% blocker provision on convertible securities. The filing does not contain new financial performance data, strategic shifts, or material events that would warrant a change in investment thesis. The continued holding by a substantial investor group is a neutral to slightly positive signal, but the limitations on their full conversion potential mean no immediate catalyst for a 'buy' or 'sell' recommendation based solely on this disclosure. Therefore, a 'hold' recommendation is appropriate as investors should await further operational or financial updates.

Keywords

Biofrontera Inc., BFRI, Schedule 13G, Beneficial Ownership, Rosalind Advisors, Rosalind Master Fund, Convertible Debt, Preferred Shares, SEC Filing, Institutional Investor, Ownership Disclosure